|
Predictive value of a CLIA-approved organoid based drug sensitivity test. |
|
|
Employment - Sengine precision medicine |
Leadership - Sengine precision medicine |
Stock and Other Ownership Interests - Sengine precision medicine |
Research Funding - Sengine precision medicine |
Patents, Royalties, Other Intellectual Property - Sengine precision medicine |
Travel, Accommodations, Expenses - Sengine precision medicine |
|
|
Employment - Sengine precision medicine |
|
|
Employment - Sengine precision medicine |
|
|
Employment - Sengine precision medicine |
Stock and Other Ownership Interests - Sengine precision medicine |
|
|
Employment - Sengine precision medicine |
|
|
Employment - Sengine Precision Oncology |
|
|
Employment - Sengine precision medicine |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Sengine precision medicine |
Stock and Other Ownership Interests - Sengine precision medicine |
|
|
Employment - Sengine Precision Medicine |
|
|
No Relationships to Disclose |
|
|
Leadership - SEngine Precision Medicine |
Stock and Other Ownership Interests - Sengine precision medicine |
Consulting or Advisory Role - bioTheranostics; Novartis; Puma Biotechnology; Seagen |
Research Funding - Agendia; Genentech/Roche (Inst); SignalOne Bio |
|
|
Employment - Sengine precision medicine |
Leadership - Sengine Precision Medicine |
Stock and Other Ownership Interests - Sengine precision medicine |
Research Funding - Sengine precision medicine |
Patents, Royalties, Other Intellectual Property - Sengine precision medicine |
Travel, Accommodations, Expenses - Sengine precision medicine |